



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Yoram Reiter

Serial No.: 10/510,229

Filed: October 13, 2004

For: ANTIGEN-PRESENTING  
COMPLEX-BINDING COMPOSITIONS  
AND USES THEREOF

Examiner: Lucas, Zachariah

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

§  
§  
§  
§  
§  
§  
§

Group Art Unit: 1648

§  
§  
§  
§

Attorney  
Docket: 28429

**DECLARATION OF YORAM REITER**  
**UNDER 37 CFR 1.132**

I, Yoram Reiter, am an inventor of the above-identified application.

I have read the Office action dated January 24, 2007 with respect to the above-identified application.

In paragraph of the Official Action, the Examiner rejected claims 141-160 under 35 U.S.C. 103(a) as being obvious over Reiter (PNAS 94:4631-4636, 1997), in view of Andersen (WO 97/02342), Saito (J. Virol. 75: 1065-71) and further in view of Hoogenboom and Reiter, (U.S. 2003/0223994), and stated that claim 150 reads on embodiments wherein the antibody used in the method comprises the sequence of SEQ ID NO:23.

I hereby declare that the subject matter of claim 150, which is described but not claimed in Hoogenboom and Reiter (U.S. 2003/0223994), was conceived solely by me and its inclusion in Hoogenboom and Reiter (U.S. 2003/0223994) was derived by me.

U.S. Patent Application 2003/0223994 to Hoogenboom and Reiter teaches protein ligands (e.g., antibodies) that bind to MHC-peptide complexes. However, while the reference discloses the amino acid sequence (SEQ ID NO:80) which comprises SEQ ID NO:23, the use of this amino acid sequence for killing or


damaging cells is not claimed in the reference. In addition, the methodology of obtaining the antibodies disclosed in U.S. 2003/0223994 application to Hoogenboom and Reiter was conceived solely by myself and its inclusion in U.S. 2003/0223994 to Hoogenboom and Reiter was derived from my sole conception and contribution.

It is therefore clear that the description of the amino acid sequence set forth in SEQ ID NO:80 in U.S. 2003/0223994 to Hoogenboom and Reiter was derived from my invention and hence the subject matter claimed in claim 150 of the instant application is not disclosed by "another", but rather derived by me.

I therefore respectfully request that the Examiner's rejections under 35 U.S.C. 103(a) should be withdrawn.

I hereby declare that all the statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and the such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: July 16, 2007



Yoram Reiter

# **CURRICULUM VITAE** (January 2007)

**YORAM REITER**

## **ACADEMIC DEGREES:**

- 1/1993 Ph.D Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel.  
Supervisor: Prof. Zvi Fishelzon
- 2/1987 M.Sc Department of Chemical Immunology, The Feinberg Graduate School The Weizmann Institute of Science, Rehovot, Israel.  
Supervisor: Prof. Zvi Fishelzon
- 8/1984 B.Sc Biochemistry, Tel Aviv University, Faculty of Life Sciences, Tel Aviv, Israel.

## **ACADEMIC APPOINTMENTS**

- 7/2003-Present Associate Professor, Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel
- 10/1998-7/2003 Senior Lecturer, Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel.

## **PROFESSIONAL EXPERIENCE:**

- 8/1997-9/1998 Senior Scientist, Peptor Ltd. Kiryat Weizmann, Rehovot, Israel
- 1/1993- 7/1997 Research fellow, Laboratory of Molecular Biology, Division of Basic Sciences, National Cancer Institute National Institutes of Health, Bethesda MD.  
Supervisor: Dr. Ira Pastan

## **RESEARCH INTERESTS:**

### **Molecular Immunology**

1. Recombinant antibody fragments for cancer immunotherapy and diagnosis.
2. Recombinant antibodies for studying anti-tumor and anti-viral immune responses
3. Antibody phage display libraries for the isolation of novel reagents for targeting cancer and autoimmune disorders.
4. Recombinant MHC molecules and their use.
5. Molecular mechanisms of T cell function and regulation.
6. Protein engineering of recombinant antibody and T-cell receptor Fv fragments.

### **TEACHING EXPERIENCE:**

1. 1986, Teaching assistant, Laboratory courses: basics of Biochemistry. The Feinberg Graduate School of The Weizmann Institute of Science, Rehovot, Israel.
2. 1987-1992, Teaching assistant, Laboratory courses: Basics of Biochemistry and Laboratory course in Immunology, The Feinberg Graduate School of The Weizmann Institute of Science, Rehovot, Israel.
3. 1998, Pharmaceutical Biotechnology and Drug Discovery, (Graduate course), Faculty of Biology, Technion.
4. 1999- Present, Biochemistry (Responsible teacher) (Undergraduate, 350 students), Faculty of Biology, Technion.
5. 2000, Cell Biology, (Undergraduate), Faculty of Biology, Technion.
6. 2000, Advanced Molecular Biology (Graduate course), Faculty of Biology, Technion.
7. 2001-present, Advanced Molecular Biotechnology, (Undergraduate and Graduate) Design and supervision of a new course. Faculty of Biology, Technion.

### **TECHNION ACTIVITIES**

2004-2006, Head of Graduate Studies, Faculty of Biology, Technion-Israel Institute of Technology

2005-2006, Member of the Technion Thesis Evaluation committee, Technion Graduate School, Technion

2005-Present, Head of Technion committee for construction of central animal facility

2005- Member of the Management Committee, The Russell Berrie Nanotechnology Institute, Technion

2006- Present, Dean, Faculty of Biology, Technion-Israel Institute of Technology

## **PUBLIC PROFESSIONAL ACTIVITIES**

### **Professional committees and responsibilities**

1999, 2001, 2002	Member of the Scientific Advisory Board for Grants in Cancer Research, Ministry of Health, Jerusalem, Israel
1999-2001	Member of Scientific Advisory Board, Immunology Section, ISF-Israel Science Foundation, Israel academy of science, Jerusalem, Israel.
2000-	Member of Scientific Advisory Board on Cancer Immunotherapy, Sharet Institute for Oncology, Hadassah Medical Center, Jerusalem, Israel.
2002-2003	Organizing committee and scientific committee, 32 <sup>nd</sup> Annual Meeting of the Israel Immunology Society.
2003	Chairman, Advisory Board for Grants in Cancer Research, Ministry of Health, Jerusalem, Israel
2003-	Scientific advisory board (SAB), Viventia Biotech. Ltd, Toronto, Canada
2004-	Scientific advisory board (SAB), The Ella Institute for Treatment and Research of Melanoma, Sheba Medical Center.
2004-	Member of the board of directors, Israel Immunology Society
2005-	Member of the Management Committee, The Russell Berrie Nanotechnology Institute, Technion
2005-	Member of the Scientific Advisory Board, National Council for Biotechnology, MOST-Ministry of Science and Technology
2006-research	Member of Scientific Evaluation Committee, Infrastructure Program for Biotechnology, Ministry of Science
2006-and	Member of Scientific Evaluation Committee, Eshkol Fellowships Grants in Gene Silencing, Ministry of Science.

### **Editorial responsibilities:**

**Associate Editor** – International Reviews of Immunology

**Reviewer:** Journal of Immunology, Immunity, Cancer Research, International Journal of Cancer, Nature Medicine, European Journal of Immunology, Journal of immunological

Methods, Immunology, Acta Biochimica et Biophysica, Nature Biotechnology, Protein Engineering, Structure, Clinical Cancer Research, Journal of Biological Chemistry.

**Other professional responsibilities:**

**Founder** – Founder of BioMimic Ltd. A bio-pharmaceutical start-up company (2004)  
 Founder of AIT-Applied Immune Technologies Ltd. A bio-pharmaceutical R&D company (2006)

**Consulting-** Scientific consultation to various biotechnology and pharmaceutical companies including: Viventia Biotech Ltd, Canada; Teva Pharmaceuticals, Israel; Peptor, Israel; Pfizer, UK;  
 Advisor to various start-up companies in Life Sciences.  
 Advisor to venture capital funds reviewing projects and companies in Life Sciences.

**MEMBERSHIP IN PROFESSIONAL SOCIETIES:**

1995- American association for Cancer Research.  
 1998- American association of immunologists.  
 1999- Israel Immunology Society

**HONORS: Prizes awards and scholarships:**

1988-1991 Ph.D. Studentship Scholarship. The Wolfson Foundation at the Weizmann Institute of Science.

1989-90 FEBS (Federation of European Biomedical Societies) Fellowship for graduate students.

1992-1993 The Rothschild Postdoctoral Fellowship Award for outstanding Ph.D. graduates.

1994 U.S. Federal Technology Transfer Award, for an outstanding scientific contribution of value to the USA. Awarded by the National Cancer Institute, National Institutes of Health, Bethesda MD.

1998-2001 The “Alon” Fellowship Award, for outstanding young scientists. Awarded by the Israel Council For Higher Education, The Israel Ministry of Education (“VATAT”).

1999 Award- The L. Naftali Science Foundation for Biology and Medicine, Jerusalem, Israel.

- 1999-2001 The Leah and Donald Lewis Academic Lectureship award administrated by the Technion-Israel Institute of Technology.
- 1999-2002 The TEVA Fellowship Award for Young Scientists in Life Sciences and Medicine. Awarded by TEVA Pharmaceutical Industries Ltd. Israel.
- 1999-2003 Research Career Development Award (RCDA), ICRF-Israel Cancer Research Fund (USA) New-York, USA.
- 2000-2001 The TEVA RESAERCH GRANT AWARD, Awarded through The Israel Academy of Sciences and Humanities by TEVA Pharmaceutical Industries Ltd., Israel.
- 2003 Citation for excellence in teaching – Center for Promotion of Teaching-Technion
- 2003 The Henry Taub Prize for Excellence in Research, Awarded by the Technion Board of Governors.
- 2004 The Juludan Prize for Application of science and technology in medicine, awarded by the Technion.
- 2005 George and Eva Klein Prize for Excellence in Cancer Research, Awarded by ISF- Israel Science Foundation, The Israel Academy of Sciences and Humanities.
- 2006 The Hershel Rich Technion Innovation Award. Awarded by the Technion Board of Governors.

## **PUBLICATIONS**

### **Theses:**

- 1) M.Sc. thesis: Immunotargeting of complement to tumor cells by monoclonal antibody-complement conjugates. The Feinberg Graduate school of The Weizmann Institute of Science, 1987.
- 2) Ph.D. thesis: Molecular mechanisms of tumor cell resistance to complement-mediated immune damage. The Feinberg Graduate school of The Weizmann Institute of Science, 1993.

### **Research papers (peer-reviewed):**

1. **Reiter, Y.**, and Fishelson, Z.: Tumor cell lysis by Antibody-complement conjugates. *Complement* 4:154-157, 1987.
2. **Reiter, Y.**, and Fishelson, Z.: Targeting of complement to tumor cells by heteroconjugates composed of antibodies and of the complement C3b. *J. Immunol.* 142: 2771-2777, 1989.

3. Fishelson, Z., Kopf, E., Pass, Y., Ross, L., and **Reiter, Y.**: Protein phosphorylation as a mechanism of resistance against complement damage. *Prog. Immunol.* 7: 205-208, 1989.
4. Yefenof, E., Benizri, R., **Reiter, Y.**, Klein, E., and Fishelson, Z.: Potentiation of target cell sensitivity to NK lysis by antibody-C3b/iC3b heteroconjugates. *J. Immunol.* 144: 1538-1543, 1990.
5. Fishelson, Z., and **Reiter, Y.**: sublytic complement attack potentiates the resistance of tumor cells to lytic doses of complement. *Compl Infl.* 8: 150, 1991.
6. Reiter, Z., **Reiter, Y.**, Fishelson, Z., Loyter, A., Nussbaum, O., and Rubinstein, M.: Class I MHC antigens are not associated with resistance to NK cell mediated cytotoxicity. *Immunobiol.* 183: 23-39, 1991.
7. **Reiter, Y.**, and Fishelson, Z.: Complement membrane attack complexes induces synthesis of large complement induced proteins (L-CIP) in human leukemic cells. *Mol. Immunol.* 29: 771-781, 1992.
8. **Reiter, Y.**, Cibotariu, A., and Fishelson, Z.: Sublytic complement attack protects tumor cells from lytic doses of antibody and complement. *J. Immunol.* 22: 1207-1213, 1992.
9. Brinkmann, U., **Reiter, Y.**, Jung, S.-h., Lee, B., and Pastan, I.: A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. *Proc. Natl. Acad. Sci. USA* 90: 7538-7542, 1993.
10. **Reiter, Y.**, Brinkmann, U., Webber, K.O., Jung, S.-h., Lee, B.K., and Pastan, I.: Engineering interchain disulfide bonds into conserved framework regions of Fv fragment: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. *Protein Eng.* 7: 697-704, 1994.
11. **Reiter, Y.**, Brinkmann, U., Kreitman, R.J., Jung, S.-h., Lee, B.K., and Pastan, I.: Stabilization of the Fv fragments in recombinant immunotoxins by disulfide-stabilized Fv fragment. *Biochemistry* 33: 5451-5459, 1994.
12. **Reiter, Y.**, Pai, L., Brinkmann, U., and Pastan, I.: Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. *Cancer Res.* 54: 2714-2718, 1994.
13. **Reiter, Y.**, Kreitman, R.J., Brinkmann, U., and Pastan, I.: Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti Tac(Fv) fragment and a truncated *Pseudomonas* exotoxin. *Int. J. Cancer.* 58: 142-149, 1994.
14. **Reiter, Y.**, Brinkmann, U., Jung, S.-h., Lee, K., Kasprzyk, P.G., King, C.R., and Pastan, I.: Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide-stabilization of the Fv fragment. *J. Biol. Chem.* 269: 18327-18331, 1994.



15. **Reiter, Y.**, Kurucz, I., Brinkmann, U., Jung, S.h., Lee, B., Segal, D.M., and Pastan, I.: Construction of a disulfide stabilized TCR Fv fragment indicates that antibody and TCR Fv frameworks are very similar in structure. *Immunity* 2: 281-287, 1995.
16. Webber, K.O., **Reiter, Y.**, Brinkmann, U., Kreitman, R.J., and Pastan, I.: Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog. *Mol. Immunol.* 32: 249-258, 1995.
17. Benhar, I., **Reiter, Y.**, Pai, L., and Pastan, I.: Administration of disulfide-stabilized B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing human tumor xenografts in mice. *Int. J. Cancer.* 62: 351-355, 1995.
18. **Reiter, Y.**, Ciobotariu, A., Jones, J., Morgan, B.P., and Fishelson, Z.: Complement membrane attack complex, perforin, and bacterial exotoxin induce in K562 cells calcium-dependent cross-protection from lysis. *J. Immunol.* 155: 2203-2210, 1995.
19. **Reiter, Y.**, Brinkmann, U., Jung, S-h., Lee, B., and Pastan, I.: Disulfide-stabilization of antibody Fvs: computer prediction and experimental evaluation. *Protein Eng.* 8: 1323-1331, 1995.
20. **Reiter, Y.**, Wright, A.F., and Pastan, I.: Recombinant single-chain and disulfide-stabilized Fv immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice. *Int. J. Cancer.* 67: 113-123, 1996.
21. **Reiter, Y.**, Brinkmann, U., Lee, B.K., and Pastan, I.: Engineering antibody Fv fragments for cancer diagnosis and therapy. *Nature Biotech.* 14: 1239-1245, 1996.
22. **Reiter, Y.**, DiCarlo, A., Engberg, J., and Pastan, I.: Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to MHC/peptide class I complexes with T-cell receptor-like specificity. *Proc. Natl. Acad. Sci. USA* 94: 4631-4636, 1997.
23. **Reiter, Y.**, and Pastan, I.: Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. *Trends in Biotech.* 16: 513-520, 1998.
24. **Reiter, Y.**, Schuck, P., Boyde, L.F., and Plaksin, D.: An antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface. *J. Mol. Biol.* 290:685-98, 1999.
25. Denkberg, G., Cohen, C.J., Segal, D., Kirkin A., and **Reiter, Y.**: Recombinant human single-chain MHC-peptide complexes made from *E. coli* by *in vitro*

- refolding: Functional single-chain MHC-peptide complexes and tetramers with tumor associated antigens. *Eur. J. Immunol.* 30: 3522-3532, 2000.
26. **Reiter, Y.:** Recombinant immunotoxins for targeted cancer cell therapy. *Adv. Cancer Res.* 81: 93-124, 2001.
  27. Jurianz, K., Ziegler, S., Donin, N., **Reiter, Y.**, Fishelson, Z., and Kirschfink, M.: K562 erthtoleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. *Int J Cancer* 93:848-854, 2001.
  28. Niv, R., Cohen, C.J., Denkberg, G., Segal, D., and **Reiter, Y.:** Antibody Engineering for Targeted Drug delivery: Applications for Recombinant Fv Immunotoxins and Fv fragments in Cancer Therapy and Diagnosis. *Current Pharmaceutical Biotechnology* 2: 19-46, 2001.
  29. Niv, R., Pirak, E., Segal, D., Assaraf, Y., and **Reiter, Y. :** Targeting multi drug resistance (MDR) tumor cells with a recombinant single-chain Fv fragment directed to P-glycoprotein. *Int. J. Cancer* 94: 864-872, 2001.
  30. Denkberg, G., Cohen, C.J., and **Reiter, Y.:** Critical role for CD8 in binding of MHC-peptide complexes to TCR: CD8 antibodies block specific binding of human tumor-specific MHC/peptide tetramers to T-cell receptor. *J. Immunol.* 167: 270-276, 2001
  31. Cohen, C.J, Denkberg, G and **Reiter, Y.:** Generation of recombinant immunotoxins for specific targeting of tumor related peptides presented by MHC molecules. Recominant Antibody Technology for Cancer Therapy. *Methods. Mol. Biol.* 207: 269-282, 2002.
  32. Benjamin L, Plaksin, D., and **Reiter, Y.:** Isolation of single-domain VH antibody fragments from phage display libraries. Recominant Antibody Technology for Cancer Therapy. *Methods. Mol. Biol.* 207: 133-143, 2002.
  33. Niv, R., Segal, D., and **Reiter, Y.:** Construction of recombinant single-chain and disulfide-stabilized Fv immunotoxins for cancer targeting. Recominant Antibody Technology for Cancer Therapy. *Methods. Mol. Biol.* 207: 255-268, 2002.
  34. Denkberg, G., Cohen, C.J., Lev, A., Chames, P., Hoogenboom, H., and **Reiter, Y.:** Direct visualization of distinct T cell epitopes derived from a melanoma tumor associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity. *Proc. Natl. Acad. Sci. USA.* 99: 9421-9426, 2002.
  35. Lev, A., Denkberg, G., Cohen, C.J., Tzukerman, M., Skorecki, K.L., Chames, P., Hoogenboom, H., and **Reiter, Y.:** Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. *Cancer Res.* 62: 3184-3194, 2002.

36. Lev, A., Novak, H., Segal, D., and **Reiter, Y.**: Recruitment of CTL activity by tumor-specific, antibody-mediated targeting of single-chain class I MHC-peptide complexes *J. Immunol.* 169: 2988-2996, 2002.
37. Denkberg, G., Kalchevsky, E., and **Reiter, Y.**: Specific modification of a tumor-derived peptide at an HLA-A2 anchor residue can influence the conformation of the MHC-peptide surface area: probing with T-cell receptor-like recombinant antibodies. *J. Immunol.* 169: 4399-407, 2002.
38. Cohen, C.J., Hoffman, N., Farago, M., , Hoogenboom, H.R., Eisenbach, L., and **Reiter, Y.**: Direct detection and quantitation of a distinct T cell epitope derived from tumor-specific epithelial cell-associated mucin (MUC1) using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. *Cancer Res.* 62: 5835-5844, 2002.
39. Apel, M., Ellenhorn, J.D., Diamond, D.J. and **Reiter, Y.**: A functional T cell Receptor Fv capable of specific targeting to antigen presenting cells. *Cancer Immunol. Immunother.* 51: 565-573, 2002.
40. Cohen, C.J., Sarig, O., Yamano, Y., Tomaru, U., Jacobson, S., and **Reiter, Y.**: Direct Phenotypic Analysis of human MHC Class I Antigen Presentation: Visualization, Quantitation, and In Situ Detection of Human Viral Epitopes Using Peptide-Specific, MHC-restricted Human Recombinant Antibodies. *J. Immunol.* 170: 4349-4361, 2003.
41. Cohen C.J., Denkberg, G., Schiffenbauer, Y., Berke, G., and **Reiter, Y.**: Simultaneous Monitoring of Binding to and Activation of Tumor-specific T Lymphocytes by Peptide-MHC. *J. Immunol. Methods* 277: 39 – 52, 2003.
42. Denkberg, G., Lev, A., Eisenbach, L., Benhar, I., and **Reiter, Y.**: Selective targeting of melanoma and antigen-presenting cells using a recombinant antibody with T-cell receptor-like specificity directed toward a melanoma differentiation antigen. *J. Immunol.* 171:2197-2207, 2003.
43. Cohen C.J., Denkberg, G., Lev, A., Epel, M., and **Reiter, Y.**: T cell receptor-like recombinant antibodies: New tools for the study antigen presentation and TCR-peptide-MHC interactions. *J. Mol. Recog.* 16: 324-332, 2003.
44. Biddison, W.E., Turner, R.V., Lev, A., Cohen, C.J., and **Reiter, Y.**: Tax and M1 peptide/HLA-A2-specific Fabs and T Cell Receptors Recognize non-identical Structural Features on peptide/HLA-A2 complexes. *J. Immunol.* 171: 3064-74 2003.
45. Haus-Cohen, M., Assaraf, Y., Benhar, I., and **Reiter, Y.**: Disruption of P-glycoprotein (Pgp) Anticancer Drug Efflux Activity by a Small Recombinant Single-chain Fv Antibody Fragment Targeted to an Extracellular Epitope. *Int. J. Cancer* 109: 750-758, 2004.

46. Oh, S., Terabe, M., Pendleton, D.C., Bhattacharyya, A., Bera, T., Epel, M., **Reiter, Y.**, Phillips, J., Linehan, J., Pastan, I., and Berzofsky, J.A.: Human CTL to wild type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. *Cancer Res.* 64: 2610-8, 2004.
47. Binyamin, L., Assaraf, Y.G., and **Reiter, Y.**: Targeting an extracellular epitope of Multi Drug Resistance Protein 1 (MRP1) by a small recombinant single-chain Fv antibody. *Int. J. Cancer* 110:882-890, 2004.
48. Yamano, Y., Cohen, C.J., Tomaru, U., Li, H-C., Takenouchi, N., Biddison, W., **Reiter, Y.**, and Jacobson, S.: Increased expression of HTLV-1 Tax11-19 peptide/HLA-A\*201 complexes on CD4+CD25+ T cells detected by TCR-like antibodies in patients with HTLV-1 associated neurologic disease. *J. Exp. Med.* 199: 1367-1377, 2004.
49. Zehn, D., Cohen, C.J., **Reiter, Y.**, and Walden, P.: Extended presentation of specific MHC-peptide complexes by mature dendritic cells compared to other types of antigen-presenting cells. *Euro. J. Immunol.* 34:1551-1560, 2004.
50. Lev, T., Noy, R., Oved, K., Novak, H., Segal, D., Walden, P., Zehn, D., and **Reiter, Y.**: Tumor-Specific Antibody-Mediated Targeting of MHC-Peptide Complexes Induces Regression of Human Tumor Xenografts *In Vivo*. *Proc. Natl. Acad. Sci. USA.* 101: 9051-9056, 2004.
51. Held, G., Matsuo, M., Gnjatich, S., Epel, M., Ritter, G., Yull, S., Tai, T., Cohen, C.J., Old, L.J., Pfreundschuh, M., **Reiter, Y.**, Hoogenboom, H.R., and Renner, C.: Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide-MHC specific antibody fragments. *Eur. J. Immunol.* 34: 2919-2929, 2004.
52. Oved, K., Lev, A., Noy, R., Segal, D., and **Reiter, Y.**: Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes. *Cancer Immunol. Immunother.* 54:867-79, 2005.
53. Kummer, M., Lev, A., **Reiter, Y.**, and Biedermann, B.C.: Vascular Endothelial Cells Have Impaired Capacity to Present Immunodominant, Antigenic Peptides - a Mechanism of Cell-type Specific Immune Escape. *J. Immunol.* 174: 1947-1953, 2005.
54. Binyamin, L., Assaraf, Y.G., and **Reiter, Y.**: ATP-dependent binding of a scFv antibody fragment directed to an extracellular epitope of the multi drug resistance protein 1 (MRP1) on live cells: implication for ATP-dependent conformational changes. *Int. J. Cancer.* 116: 703-9, 2005.
55. Tzukerman M., Rosenberg T., Reiter I, Ben-Eliezer S., Denkberg G., Coleman R., **Reiter Y.**, and Skorecki K. (2006). The Influence of a Human Embryonic Stem Cell Derived Microenvironment upon Targeting of Human Solid Tumor Xenografts. *Can. Res.* 66: 3792-3801, 2006.

56. Artzi, A., Benhar, I, **Reiter, Y** and Sivan, U.: Antibody Molecules Discriminate between Crystalline Facets of a Gallium Arsenide Semiconductor. *Nano letters*. 6:1870-1874, 2006.
57. Zehn, D., Cohen, C.J., **Reiter, Y.**, and Walden, P. Efficiency of peptide presentation by dendritic cells compared to other cell types: Implications for cross-priming. *Int. immunol.* 18:1647-54, 2006.
58. Novak, H., Wels, W., Zehn, D., and **Reiter, Y.**: Antibody- mediated selective targeting of antigenic MHC-peptide complexes induces efficient killing in vitro and in vivo of EGFR1-expressing tumor cells by tumor or viral-specific cytotoxic T lymphocytes. *Int. J. Cancer* 120:329-36. 2007.
59. Oved, k., Ziv, O., Jacob-Hirsch, J., Novak, H., Makler, O., Denkberg, G, Sinik, K., Segal, D., Noy, R., Gefen-Dor, C., Amariglio, N., Rechavi, G., and **Reiter, Y.** A Novel Post Priming Regulatory Check Point of Effector/Memory T cells Dictated Through Antigen Density Threshold-dependent Anergy. *J. Immunol.* 178:2307-17, 2007.

#### **Review papers:**

60. **Reiter, Y.**, and Pastan, I.: Antibody engineering of recombinant Fv-immunotoxins for improved targeting of cancer. *Clin. Cancer Res.* 2: 245-252, 1996.
61. **Reiter, Y.**, Brinkmann, U., Lee, B.K., and Pastan, I.: Engineering antibody Fv fragments for cancer diagnosis and therapy. *Nature Biotech.* 14: 1239-1245, 1996.
62. **Reiter, Y.**: Recombinant immunotoxins for targeted cancer cell therapy. *Adv. Cancer Res.* 81: 93-124, 2001.
63. Noy, R., Epel, M., Haus-Cohen, M., Klechevsky, E., Makler, O., Michaeli, Y., Denkberg, G., and **Reiter, Y.**: T cell receptor-like antibodies: novel reagents for clinical immunology and immunotherapy. *Expert. Rev. Anticancer Ther.* 5: 523-536, 2005.
64. Shadel, O., and **Reiter, Y.**: Antibodies and their fragments as anticancer agents. *Curr Pharm Des.* 12: 363-378, 2006.
65. Denkberg, G., and **Reiter, Y.**: Recombinant antibodies with T-cell receptor-like specificity: Novel tools to study MHC class I presentation. *Autoimmunity Rev.* 5: 252-257, 2006.
66. Michaeli, Y., and **Reiter, Y.**: Optimized Fc variants with enhanced effector function. *Expert Opin. Ther. Patents* 16:1449-1452, 2006.

### **Book Chapters:**

67. **Reiter, Y.**, and Fishelson, Z.: Killing of human tumor cells by antibody-C3b conjugates and human complement. In Radwell, J.D. (Ed.): Targeted Antibodies for Diagnosis and Therapy. New York, Marcel Dekker Inc., 1989, pp. 119-135.
68. Fishelson, Z., and **Reiter, Y.**: Monoclonal Antibody-C3b conjugates: killing of K562 cells and selection of a stable complement resistant variant. In Grogoman, J., Evans, C., and Golde, D. (Eds.): Mechanisms of Action and Therapeutic Application on Biologicals in Cancer and Immune Deficiency Disorders. New York, Alan R. Liss, Inc., 1989, pp. 272-282.
69. **Reiter, Y.**, Lee, B.K., and Pastan, I.: Disulfide stabilized Fvs. In: Antibody Engineering: technologies and applications. IBC Biomedical Library Series, IBC press. Pp. 147-169, 1996.
70. **Reiter, Y.**, Dicarlo, A., Engberg., and Pastan, I.: Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to MHC/peptide class I complexes with T-cell receptor-like specificity. In Antibody engineering new technologies and applications IBC Biomedical library IBC press pp.235-245,1997.
71. **Reiter, Y.** Denkberg, G, Cohen, CJ.: Engineering immunotoxins for improving their therapeutic activity. In Chimeric toxins: Mechanisms of action and therapeutic applications. Lazarovici, P., and Lorberboum-Galski, H., Eds.Harwood Academic Pub. pp 99-134, 2002.
72. Benhar, I., and **Reiter, Y.**: Phage display of single-chain antibody (scFv) constructs. *Current Protocols in Immunology*. 48:10.4 pp 59-87, 2002.
73. **Reiter, Y.** and Lev, A.,: Immunotoxins in cancer therapy. In Cancer Immune Therapy: Experiences and Future Directions, Gernot Stuhler and Peter Walden Eds. Wiley-VCH pp. 347-379, 2002.
74. Lev, A., Denkberg, G., Cohen, CJ., Hoogenboom, HR, and **Reiter, Y.**: Unexpected high frequency of Recombinant Antibodies endowed with the antigen-specific MHC-restricted specificity of T Cells isolated from a large naïve human library. *Tumor Microenvironment: Progression, Therapy and Prevention*. Monduzzi Editore press pp. 163-167, 2002.
75. Lev, A., Novak, H., Segal, D., and **Reiter, Y.**: Directing cytotoxic T cells to tumor cells by Antibody-mediated Targeting of Single-chain Class I MHC-peptide complexes. *Tumor Microenvironment: Progression, Therapy and Prevention* Monduzzi Editore press. Pp. 169-174, 2002.
76. **Reiter, Y.** and Lev, A. Immunotoxins and recombinant immunotoxins in cancer therapy. Encyclopedia of Molecular Cell Biology and Molecular Medicine. Ed. R. Meyer, Wiley-VCH pp 497-529, 2004.